Tearsheet

ImmuCell (ICCC)

Market Price (12/27/2025): $6.13 | Market Cap: $55.5 Mil
Sector: Health Care | Industry: Biotechnology

ImmuCell (ICCC)

Market Price (12/27/2025): $6.13
Market Cap: $55.5 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0	Megatrend and thematic drivers Megatrends include Animal Health & Biotechnology, and Sustainable Agriculture. Themes include Veterinary Therapeutics, Livestock Disease Prevention, Show more.	Weak multi-year price returns 2Y Excs Rtn is -12%, 3Y Excs Rtn is -84%	Expensive valuation multiples P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 28x
1			Weak revenue growth Rev Chg QQuarterly Revenue Change % is -8.4%
2			Key risks ICCC key risks include [1] failure to obtain FDA approval for its key growth product, Show more.

0	Megatrend and thematic drivers Megatrends include Animal Health & Biotechnology, and Sustainable Agriculture. Themes include Veterinary Therapeutics, Livestock Disease Prevention, Show more.
1	Weak multi-year price returns 2Y Excs Rtn is -12%, 3Y Excs Rtn is -84%
2	Expensive valuation multiples P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 28x
3	Weak revenue growth Rev Chg QQuarterly Revenue Change % is -8.4%
4	Key risks ICCC key risks include [1] failure to obtain FDA approval for its key growth product, Show more.

Valuation, Metrics & Events

	12/27/25	2024	2023	2022	2021
Share Price CYE	$6.13	$5.15	$5.09	$6.10	$8.00
Market Cap CYE ($ Mil)	55.5	46.1	39.4	47.3	61.9
Total Debt ($ Mil)	13.6	15.1	16.7	12.5	10.3
Total Cash ($ Mil)	3.9	3.8	1.0	5.8	10.2
Enterprise Value ($ Mil)	65.2	61.2	56.1	59.8	72.2
Valuation Ratios
P/S TTM	2.0	1.6	2.3	2.5	3.2
P/EBIT TTM	19.7	-26.0	-7.4	-22.1	255.9
P/E TTM	23.9	-19.5	-6.8	-18.9	-775.8
P/FCF TTM	77.5	-390.1	-6.0	-8.6	-36.7
Sector Ratios
P/S TTM (Sector)	4.3	3.5	3.9	4.5	7.1
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4	-1.3	-2.6
P/E TTM (Sector)	-1.7	-1.5	-1.5	-1.3	-2.8
P/FCF TTM (Sector)	-1.5	-1.4	-1.4	-1.5	-3.2

	12/27/25	2024	2023
Share Price CYE	$6.13	$5.15	$5.09
Market Cap CYE ($ Mil)	55.5	46.1	39.4
Total Debt ($ Mil)	13.6	15.1	16.7
Total Cash ($ Mil)	3.9	3.8	1.0
Enterprise Value ($ Mil)	65.2	61.2	56.1
Valuation Ratios
P/S TTM	2.0	1.6	2.3
P/EBIT TTM	19.7	-26.0	-7.4
P/E TTM	23.9	-19.5	-6.8
P/FCF TTM	77.5	-390.1	-6.0
Sector Ratios
P/S TTM (Sector)	4.3	3.5	3.9
P/EBIT TTM (Sector)	-1.5	-1.3	-1.4
P/E TTM (Sector)	-1.7	-1.5	-1.5
P/FCF TTM (Sector)	-1.5	-1.4	-1.4

	ICCC	S&P 500
REVENUE GROWTH
Rev LTM ($ Bil)	0.0
Rev Chg Q	-8.4%	7.3%
Rev Chg LTM	16.5%	6.1%
Rev Chg 3Y Avg	14.6%	5.5%
PROFITABILITY	POOR
Op Inc LTM ($ Bil)	0.0
CFO LTM ($ Bil)	0.0
Net Inc LTM ($ Bil)	0.0
Op Mgn LTM	8.4%	18.8%
CFO/Rev LTM	7.2%	20.4%
Net Inc Mgn	8.4%	13.1%
VALUATION	HIGH
P/S	2.0	3.3
P/CFO	27.9	15.8
P/FCF	77.5	20.7
P/E	23.9	23.5
STABILITY	GOOD
Debt/Equity	0.25	0.21
Cash/Assets	0.08	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
Order Backlog	under $100,000	6302025	Link
Annual Production Capacity	over $30 million	7092025	Link
Tri-Shield Sales Share	71% of total sales	3312025	Link
Total Doses Sold (First Defense product line)	over 36 million doses	3282025	Link

Upcoming
2/25/2026	Earnings Release	Rev: - EPS: -

ICCC Stock

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Here are the key points explaining the approximate -4.4% movement in ImmuCell (ICCC) stock from August 31, 2025, to December 27, 2025:

1. ImmuCell's Q3 2025 earnings report on November 14, 2025, showed mixed results, leading to a 7.79% drop in share price. The company reported an 8% decrease in Q3 2025 product sales, totaling $5.5 million compared to $6.0 million in Q3 2024, and posted a net loss of $0.1 million, or ($0.02) per share.

2. The company received an FDA Incomplete Letter for its Re-Tain New Animal Drug Application (NADA) on December 23, 2025. This was attributed to unresolved inspectional deficiencies at a contract manufacturer, leading ImmuCell to pause further investment in Re-Tain and redirect resources to its First Defense franchise.

3. ImmuCell anticipates a non-cash impairment write-down of approximately $2.3 million in Q4 2025. This expected impairment is a direct consequence of the strategic shift away from the Re-Tain product line, whose net book value of assets was approximately $15.5 million as of September 30, 2025.

4. The stock price crossed below its 200-day moving average in December 2025. This technical indicator, coupled with negative analyst sentiment, including a reiterated "Sell" rating from Weiss Ratings and an average "Sell" rating from MarketBeat, contributed to downward pressure on the stock.

5. Preliminary Q3 2025 sales results, announced on October 7, 2025, indicated a softening of sales. ImmuCell reported preliminary Q3 2025 product sales of $5.5 million, an 8% decline from the prior year, and warned of a likely second-half 2025 sales softening due to backlog depletion.

Stock Movement Drivers

Fundamental Drivers

The 1.5% change in ICCC stock from 9/26/2025 to 12/26/2025 was primarily driven by a 34.3% change in the company's Net Income Margin (%).

	9262025	12262025	Change
Stock Price ($)	6.03	6.12	1.49%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	28.27	27.77	-1.79%
Net Income Margin (%)	6.23%	8.37%	34.30%
P/E Multiple	30.91	23.82	-22.93%
Shares Outstanding (Mil)	9.03	9.05	-0.16%
Cumulative Contribution			1.49%

LTM = Last Twelve Months as of date shown

Market Drivers

9/26/2025 to 12/26/2025

	Return	Correlation
ICCC	1.5%
Market (SPY)	4.3%	18.5%
Sector (XLV)	15.2%	20.7%

Fundamental Drivers

The -9.3% change in ICCC stock from 6/27/2025 to 12/26/2025 was primarily driven by a -10.2% change in the company's P/S Multiple.

	6272025	12262025	Change
Stock Price ($)	6.75	6.12	-9.33%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	27.30	27.77	1.71%
P/S Multiple	2.22	1.99	-10.21%
Shares Outstanding (Mil)	8.98	9.05	-0.73%
Cumulative Contribution			-9.34%

LTM = Last Twelve Months as of date shown

Market Drivers

6/27/2025 to 12/26/2025

	Return	Correlation
ICCC	-9.3%
Market (SPY)	12.6%	27.4%
Sector (XLV)	17.0%	12.9%

Fundamental Drivers

The 28.8% change in ICCC stock from 12/26/2024 to 12/26/2025 was primarily driven by a 22.5% change in the company's P/S Multiple.

	12262024	12262025	Change
Stock Price ($)	4.75	6.12	28.84%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	23.84	27.77	16.49%
P/S Multiple	1.63	1.99	22.54%
Shares Outstanding (Mil)	8.16	9.05	-10.80%
Cumulative Contribution			27.34%

LTM = Last Twelve Months as of date shown

Market Drivers

12/26/2024 to 12/26/2025

	Return	Correlation
ICCC	28.8%
Market (SPY)	15.8%	12.2%
Sector (XLV)	13.3%	10.4%

Fundamental Drivers

The -3.8% change in ICCC stock from 12/27/2022 to 12/26/2025 was primarily driven by a -18.7% change in the company's P/S Multiple.

	12272022	12262025	Change
Stock Price ($)	6.36	6.12	-3.77%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	20.10	27.77	38.15%
P/S Multiple	2.45	1.99	-18.67%
Shares Outstanding (Mil)	7.75	9.05	-16.77%
Cumulative Contribution			-6.48%

LTM = Last Twelve Months as of date shown

Market Drivers

12/27/2023 to 12/26/2025

	Return	Correlation
ICCC	29.9%
Market (SPY)	48.0%	9.0%
Sector (XLV)	18.2%	8.0%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
ICCC Return	16%	34%	-24%	-17%	1%	13%	13%
Peers Return	16%	38%	-12%	21%	26%	16%	150%
S&P 500 Return	16%	27%	-19%	24%	23%	18%	114%
Monthly Win Rates [3]
ICCC Win Rate	67%	50%	67%	42%	42%	50%
Peers Win Rate	52%	65%	42%	68%	57%	52%
S&P 500 Win Rate	58%	75%	42%	67%	75%	73%
Max Drawdowns [4]
ICCC Max Drawdown	-26%	0%	-24%	-27%	-31%	-11%
Peers Max Drawdown	-34%	-5%	-26%	-7%	-9%	-23%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: HPQ, HPE, IBM, CSCO, AAPL.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/26/2025 (YTD)

How Low Can It Go

Unique Key	Event	ICCC	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-62.5%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	167.0%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-36.0%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	56.2%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	104 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-47.9%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	91.9%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	434 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-77.8%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	351.4%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	840 days	1,480 days

Compare to HPQ, HPE, IBM, CSCO, AAPL

In The Past

ImmuCell's stock fell -62.5% during the 2022 Inflation Shock from a high on 2/19/2021. A -62.5% loss requires a 167.0% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About ImmuCell (ICCC)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

AI Analysis | Feedback

Here are 1-3 brief analogies for ImmuCell (ICCC):

Zoetis for cattle immunity.
A biotech company for cows.

AI Analysis | Feedback

First Defense®: A bovine health supplement providing newborn calves with immediate immunity against common scours-causing pathogens like *E. coli* K99 and bovine coronavirus.
Re-Tain®: An antibiotic-free intramammary treatment for clinical mastitis in lactating dairy cows.

AI Analysis | Feedback

ImmuCell (ICCC) primarily sells its animal health products to other companies rather than directly to individuals. Its major direct customers are **Animal Health Distributors**.

While ImmuCell's public filings indicate that a significant portion of its revenue is derived from sales to a limited number of distributors, the company does not publicly disclose the specific names of these major customer companies. Therefore, no specific company names or public symbols can be provided.

However, the key categories of end-users for ImmuCell's products, typically reached through these distributors, include:

Veterinary Clinics and Practices: Professionals in these settings recommend and use ImmuCell's products, such as the First Defense® line, for the health management of dairy and beef cattle.
Dairy Cattle Producers: Farms focused on milk production utilize ImmuCell's products to support the health and immunity of their calves and control mastitis in lactating cows.
Beef Cattle Producers: Ranchers and farms raising beef cattle also use ImmuCell's products to enhance the health and productivity of their herds.

AI Analysis | Feedback

null

AI Analysis | Feedback

Olivier te Boekhorst, President and CEO

Mr. te Boekhorst assumed the role of President and CEO on November 1, 2025. He previously served as an Operating Partner at ARCHIMED, a global investment firm specializing in human and animal healthcare. His experience includes serving as Chair of the Board and former CEO of SeqCenter, a Next Generation Sequencing laboratory. From 2004 to 2022, Mr. te Boekhorst held various leadership positions at IDEXX Laboratories, where he directed M&A activities for the livestock diagnostics segment and expanded several divisions, including livestock and dairy diagnostics, water safety testing, and human diagnostics. He also worked for the Boston Consulting Group and earned an MBA from Cornell University.

Timothy C. Fiori, CFO, Treasurer and Secretary

Mr. Fiori joined ImmuCell as CFO in April 2025 and was appointed to the Board of Directors on October 29, 2025, also serving as Treasurer and Secretary. He brings 24 years of finance and commercial operating experience within the livestock industry, having spent that time at IDEXX Laboratories. Mr. Fiori holds a finance degree from the University of Maine.

Michael F. Brigham, Special Advisor to the Chief Executive Officer, Director

Mr. Brigham served as President and CEO of ImmuCell from February 2000 through October 2025, and previously as Chief Financial Officer from October 1991. He initially joined ImmuCell in 1989. Prior to his tenure at ImmuCell, he worked as an auditor at Ernst & Young for nearly six years.

AI Analysis | Feedback

The key risks to ImmuCell's business include:

Regulatory Approval for Re-Tain®: The successful development and commercialization of Re-Tain®, a novel treatment for subclinical mastitis, is contingent upon obtaining FDA approval. Delays or failure to secure this approval would significantly impact ImmuCell's future growth prospects, as Re-Tain® is positioned to address a substantial market opportunity in the dairy industry.
Production Capacity and Supply Chain Challenges: ImmuCell faces ongoing risks related to its manufacturing capabilities and supply chain. These include potential difficulties or delays in expanding production capacity, ensuring alignment between manufacturing resources and product demand, and mitigating the impact of supply chain disruptions. The company has previously experienced prolonged order backlogs that affected sales. Additionally, the ability to obtain colostrum that meets its specifications is critical for its products, particularly the First Defense® line.
Market Competition and Customer Acceptance: ImmuCell operates in a competitive animal health market. The company's success depends on its ability to compete effectively against other established animal health companies and to achieve broad customer acceptance for both its existing First Defense® product line and any new products, such as Re-Tain®, upon launch.

AI Analysis | Feedback

null

AI Analysis | Feedback

ImmuCell (ICCC) focuses on animal health products for dairy and beef industries, primarily addressing calf scours and mastitis in cows.

First Defense® Product Line (Calf Scours Prevention)

The global addressable market for calf scour treatments was approximately USD 1.29 billion in 2024 and is projected to grow to USD 2.05 billion by 2033. This market size is global.

Re-Tain® (Bovine Mastitis Treatment)

The global addressable market for bovine mastitis treatment was approximately USD 2.0 billion in 2024 and is expected to reach USD 3.7 billion by 2034. Another estimate places the global market at USD 2.15 billion in 2024, expected to reach USD 4.06 billion by 2032. The U.S. bovine mastitis market was valued at USD 683 million in 2023.

AI Analysis | Feedback

ImmuCell (ICCC) is anticipated to drive future revenue growth over the next 2-3 years through several key initiatives:

Commercialization of Re-Tain: The potential FDA approval and subsequent full-scale commercial launch of Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is a significant expected revenue driver. The company is currently conducting investigational product use studies to gather market feedback and data to prepare for this launch.
Expansion of the First Defense® product line: ImmuCell expects continued growth from its flagship First Defense® product line, including the introduction of new products such as a bulk powder formulation targeting large calf-raising ranches, which represents an expansion into a new market segment.
Increased production capacity and operational efficiencies: The completion of investments to expand the production capacity for the First Defense® product line, aimed at supporting over $30 million in annual revenue, along with stabilized production and improved gross margins, will enable the company to meet increased demand and drive higher sales.
International market expansion for First Defense®: ImmuCell is pursuing regulatory approvals to introduce its First Defense® product line into selected international territories, which could open up new significant revenue streams.

AI Analysis | Feedback

Share Issuance

From the first quarter of 2016 through the second quarter of 2021, ImmuCell issued approximately 4,553,017 shares of common stock, raising gross proceeds of approximately $26.7 million across six separate transactions.
During 2024, the company issued 1,228,227 shares of common stock, generating gross proceeds of approximately $4.6 million through an At-The-Market (ATM) Offering.
As of March 21, 2025, ImmuCell had 15,000,000 common shares authorized and 8,982,623 common shares outstanding.

Capital Expenditures

ImmuCell has made significant investments to increase its production capacity for the First Defense® product line to approximately $30 million or more per year, with facility expansions and new equipment completed by the end of 2022.
Between 2000 and 2024, the company invested an aggregate of approximately $30.2 million in direct expenditures for the development of Re-Tain®, a purified Nisin treatment for subclinical mastitis.
In 2023 and 2024, the company deferred large capital expenditure projects, including approximately $3 million to further increase First Defense® capacity and around $2 million for an in-house aseptic filling facility for Re-Tain®, to conserve cash.

Better Bets than ImmuCell (ICCC)

INDUSTRY: Biotechnology

Higher Rev Chg 3Y Avg | Lower P/S (Values for ICCC: 14.6% | 2.0x)

SRPT (40.6% | 0.9x)

Sarepta Therapeutics

ATRA (689.7% | 1.5x)

Atara Biotherapeutics

HRTX (16.6% | 1.4x)

Heron Therapeutics

ARCT (125.6% | 2.0x)

Arcturus Therapeutics

CHRS (30.9% | 0.6x)

Coherus Oncology

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ICCC: 14.6% | 23.8x)

UTHR (19.0% | 14.6x)

United Therapeutics

BMRN (15.5% | 18.7x)

BioMarin Pharmaceutical

HALO (29.0% | 10.9x)

Halozyme Therapeutics

PTCT (41.7% | 6.7x)

PTC Therapeutics

CPRX (46.5% | 11.5x)

Catalyst Pharmaceuticals

Higher Rev Chg LTM (Value for ICCC: 16.5%)

BBIO (62.5%)

BridgeBio Pharma

ALNY (53.2%)

Alnylam Pharmaceuticals

INSM (30.3%)

Insmed

NBIX (19.6%)

Neurocrine Biosciences

INCY (18.1%)

Incyte

Higher Rev Chg 3Y Avg (Value for ICCC: 14.6%)

BBIO (727.6%)

BridgeBio Pharma

ALNY (51.4%)

Alnylam Pharmaceuticals

NBIX (24.6%)

Neurocrine Biosciences

INSM (22.8%)

Insmed

UTHR (19.0%)

United Therapeutics

Higher Op Mgn LTM (Value for ICCC: 8.4%)

GILD (38.3%)

Gilead Sciences

REGN (26.7%)

Regeneron Pharmaceuticals

BIIB (24.8%)

Biogen

AMGN (24.1%)

Amgen

ABBV (24.1%)

AbbVie

Higher CFO/Rev LTM (Value for ICCC: 7.2%)

AMGN (36.5%)

Amgen

REGN (35.6%)

Regeneron Pharmaceuticals

ABBV (35.0%)

AbbVie

GILD (33.2%)

Gilead Sciences

VRTX (31.7%)

Vertex Pharmaceuticals

Higher FCF/Rev LTM (Value for ICCC: 2.6%)

ABBV (33.0%)

AbbVie

AMGN (32.1%)

Amgen

GILD (31.5%)

Gilead Sciences

VRTX (28.5%)

Vertex Pharmaceuticals

REGN (27.2%)

Regeneron Pharmaceuticals

Higher Total Yield (Value for ICCC: 4.2%)

GILD (7.8%)

Gilead Sciences

AMGN (6.7%)

Amgen

BIIB (6.2%)

Biogen

REGN (6.0%)

Regeneron Pharmaceuticals

UTHR (5.7%)

United Therapeutics

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for ICCC: 14.6% | 2.0x)

BTSG (24.3% | 0.6x)

BrightSpring Health Services

OSCR (46.4% | 0.3x)

Oscar Health

ALHC (38.8% | 1.0x)

Alignment Healthcare

PRVA (17.4% | 1.5x)

Privia Health

PGNY (23.1% | 1.7x)

Progyny

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ICCC: 14.6% | 23.8x)

UTHR (19.0% | 14.6x)

United Therapeutics

BMRN (15.5% | 18.7x)

BioMarin Pharmaceutical

HALO (29.0% | 10.9x)

Halozyme Therapeutics

BTSG (24.3% | 22.5x)

BrightSpring Health Services

PTCT (41.7% | 6.7x)

PTC Therapeutics

Higher Rev Chg LTM (Value for ICCC: 16.5%)

LLY (36.8%)

Eli Lilly

ISRG (22.2%)

Intuitive Surgical

BSX (21.6%)

Boston Scientific

CI (20.9%)

Cigna

MCK (17.2%)

McKesson

Higher Rev Chg 3Y Avg (Value for ICCC: 14.6%)

ALNY (51.4%)

Alnylam Pharmaceuticals

LLY (23.4%)

Eli Lilly

INSM (22.8%)

Insmed

ISRG (16.3%)

Intuitive Surgical

BSX (15.6%)

Boston Scientific

Higher Op Mgn LTM (Value for ICCC: 8.4%)

LLY (43.0%)

Eli Lilly

MRK (34.9%)

Merck

JNJ (26.2%)

Johnson & Johnson

ABBV (24.1%)

AbbVie

TMO (18.4%)

Thermo Fisher Scientific

Higher CFO/Rev LTM (Value for ICCC: 7.2%)

ABBV (35.0%)

AbbVie

MRK (26.6%)

Merck

JNJ (26.3%)

Johnson & Johnson

LLY (20.5%)

Eli Lilly

TMO (17.5%)

Thermo Fisher Scientific

Higher FCF/Rev LTM (Value for ICCC: 2.6%)

ABBV (33.0%)

AbbVie

MRK (20.3%)

Merck

JNJ (20.3%)

Johnson & Johnson

TMO (14.0%)

Thermo Fisher Scientific

UNH (4.0%)

UnitedHealth

Higher Total Yield (Value for ICCC: 4.2%)

MRK (10.2%)

Merck

UNH (8.5%)

UnitedHealth

ABT (8.3%)

Abbott Laboratories

JNJ (7.5%)

Johnson & Johnson

AMGN (6.7%)

Amgen

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for ICCC: 14.6% | 2.0x)

PGR (20.6% | 1.6x)

Progressive

WBD (17.2% | 1.9x)

Warner Bros. Discovery

OKE (16.4% | 1.5x)

ONEOK

CPNG (18.4% | 1.3x)

Coupang

CCL (45.9% | 1.5x)

Carnival

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ICCC: 14.6% | 23.8x)

META (17.3% | 20.4x)

Meta Platforms

MU (28.3% | 23.3x)

Micron Technology

BKNG (17.8% | 19.6x)

Booking

NEM (23.9% | 12.4x)

Newmont

AEM (26.0% | 17.6x)

Agnico Eagle Mines

Higher Rev Chg LTM (Value for ICCC: 16.5%)

NVDA (65.2%)

NVIDIA

PLTR (47.2%)

Palantir Technologies

AMD (31.8%)

Advanced Micro Devices

AVGO (23.9%)

Broadcom

META (21.3%)

Meta Platforms

Higher Rev Chg 3Y Avg (Value for ICCC: 14.6%)

NVDA (91.6%)

NVIDIA

PLTR (29.3%)

Palantir Technologies

AVGO (25.2%)

Broadcom

BRK-B (19.8%)

Berkshire Hathaway

META (17.3%)

Meta Platforms

Higher Op Mgn LTM (Value for ICCC: 8.4%)

NVDA (58.8%)

NVIDIA

MSFT (46.3%)

Microsoft

GOOGL (32.2%)

Alphabet

AAPL (31.9%)

Apple

AMZN (11.4%)

Amazon.com

Higher CFO/Rev LTM (Value for ICCC: 7.2%)

MSFT (50.0%)

Microsoft

NVDA (44.4%)

NVIDIA

GOOGL (39.3%)

Alphabet

AAPL (26.6%)

Apple

AMZN (18.1%)

Amazon.com

Higher FCF/Rev LTM (Value for ICCC: 2.6%)

NVDA (41.3%)

NVIDIA

MSFT (26.6%)

Microsoft

META (23.7%)

Meta Platforms

AAPL (23.5%)

Apple

GOOGL (19.1%)

Alphabet

Higher Total Yield (Value for ICCC: 4.2%)

XOM (9.2%)

Exxon Mobil

BAC (7.1%)

Bank of America

JPM (6.4%)

JPMorgan Chase

BRK-B (6.3%)

Berkshire Hathaway

V (5.1%)

Visa

		Best Bets In Health Care Sector
	ICCC	RPRX	HALO	DOCS	CPRX	HRMY	LGND	ISRG	GMED	MD	HIMS
What You Pay
P/E	23.8	22.1	13.6	32.4	13.7	11.8	78.9	75.0	28.1	11.4	58.0
P/EBIT	19.7	10.7	10.6	33.2	11.5	8.9	57.4	73.2	27.4	7.7	67.5
What You Get
Rev Chg Q	-8.4%	7.9%	22.1%	23.2%	15.3%	28.7%	122.8%	22.9%	22.9%	-3.6%	49.2%
Rev Chg LTM	16.5%	3.7%	31.2%	20.2%	25.6%	21.1%	64.8%	22.2%	11.7%	-4.2%	78.0%
Rev Chg 3Y Avg	14.6%	1.5%	29.0%	17.4%	46.5%	27.4%	16.0%	16.3%	45.6%	-0.5%	71.0%
FCF/Rev 3Y Avg	-17.6%	115.2%	45.0%	42.7%	34.2%	33.2%	23.9%	16.5%	14.3%	8.9%	6.9%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	ImmuCell Earnings Notes
2	Would You Still Hold ImmuCell Stock If It Fell 30%?	Return

	Title
0	ARTICLES

Trade Ideas

Select ideas related to ICCC. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	21.4%	21.4%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-7.4%	-7.4%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	18.0%	18.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.9%	3.9%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	12.2%	12.2%	-5.1%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
ZETA	Zeta Global	4.6	8.3%	15.1%
SGML	Sigma Lithium	1.6	7.3%	29.2%
USAS	Americas Gold And Silver	1.6	6.6%	557.6%
CPNG	Coupang	44.2	6.4%	10.4%
LION	Lionsgate Studios	2.7	4.6%	-69.9%
BBW	Build-A-Bear Workshop	0.8	4.4%	37.8%
XRAY	Dentsply Sirona	2.3	4.2%	-36.3%
BLMN	Bloomin Brands	0.6	3.8%	-41.2%
FUN	Six Flags Entertainment	1.5	3.8%	-69.1%
SVM	Silvercorp Metals	1.9	3.6%	198.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FLY	Firefly Aerospace	3.3	-13.7%	-61.3%
TMC	TMC The Metals	2.5	-10.5%	508.9%
ORGO	Organogenesis	0.7	-10.1%	64.8%
AAOI	Applied Optoelectronics	2.4	-9.3%	0.8%
BKSY	BlackSky Technology	0.7	-9.0%	79.0%
LUNR	Intuitive Machines	1.8	-8.7%	-16.0%
RCAT	Red Cat	0.8	-8.7%	-35.4%
RGTI	Rigetti Computing	6.7	-8.7%	46.7%
RDW	Redwire	1.0	-8.6%	-56.6%
RKLB	Rocket Lab	36.4	-8.5%	177.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
OMER	Omeros	0.9	71.5%	59.0%
RZLT	Rezolute	0.3	44.3%	-45.5%
DVAX	Dynavax Technologies	1.8	41.5%	20.4%
LUNR	Intuitive Machines	1.8	40.6%	-16.0%
UAMY	United States Antimony	0.7	39.0%	252.5%
FOLD	Amicus Therapeutics	4.4	30.9%	51.3%
ADEA	Adeia	1.9	30.3%	23.0%
HUT	Hut 8	5.2	28.6%	142.3%
AAOI	Applied Optoelectronics	2.4	27.1%	0.8%
SGML	Sigma Lithium	1.6	24.9%	29.2%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TPL	Texas Pacific Land	6.6	-67.9%	-21.5%
LW	Lamb Weston	5.9	-29.0%	-35.3%
TLRY	Tilray Brands	10.2	-22.2%	-27.8%
TDUP	ThredUp	0.8	-18.2%	348.2%
LAB	Standard BioTools	0.5	-16.9%	-21.1%
OLMA	Olema Pharmaceuticals	2.2	-14.9%	349.9%
EVEX	Eve	1.4	-12.0%	-21.9%
IRON	Disc Medicine	2.8	-11.2%	26.7%
AVO	Mission Produce	0.8	-11.1%	-18.8%
CABO	Cable One	0.7	-10.6%	-67.4%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
TLRY	Tilray Brands	10.2	876.4%	-27.8%
HPP	Hudson Pacific Properties	4.7	452.7%	-51.0%
WVE	WAVE Life Sciences	2.9	139.2%	43.7%
TE	T1 Energy	1.1	106.7%	400.0%
VERA	Vera Therapeutics	3.4	82.1%	26.7%
OMER	Omeros	0.9	66.2%	59.0%
RKLB	Rocket Lab	36.4	65.8%	177.4%
PL	Planet Labs PBC	5.9	65.0%	379.2%
AAOI	Applied Optoelectronics	2.4	63.5%	0.8%
LUNR	Intuitive Machines	1.8	62.4%	-16.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
RZLT	Rezolute	0.3	-72.0%	-45.5%
JANX	Janux Therapeutics	0.9	-59.0%	-73.4%
FRMI	Fermi	5.3	-46.0%	-76.6%
LENZ	LENZ Therapeutics	0.5	-43.5%	-41.6%
GOGO	Gogo	0.6	-35.3%	-43.0%
HPK	HighPeak Energy	0.5	-33.9%	-70.4%
PACB	Pacific Biosciences of California	0.5	-32.7%	-3.3%
LDI	loanDepot	0.4	-29.6%	3.9%
ORIC	ORIC Pharmaceuticals	0.6	-29.0%	2.2%
LW	Lamb Weston	5.9	-28.6%	-35.3%

Peer Comparisons for ImmuCell

Peers to compare with:

Financials

	ICCC	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	ImmuCell	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Price	6.12	23.26	24.49	305.09	78.16	273.40	51.32
Mkt Cap	0.1	21.9	32.6	284.9	309.2	4,074.4	158.8
Rev LTM	28	55,295	34,296	65,402	57,696	408,625	56,496
Op Inc LTM	2	3,624	1,644	11,544	12,991	130,214	7,584
FCF LTM	1	2,800	627	11,854	12,733	96,184	7,327
FCF 3Y Avg	-3	2,978	1,400	11,753	13,879	100,503	7,366
CFO LTM	2	3,697	2,919	13,483	13,744	108,565	8,590
CFO 3Y Avg	-1	3,672	3,896	13,498	14,736	111,559	8,697

Growth & Margins

	ICCC	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	ImmuCell	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Rev Chg LTM	16.5%	3.2%	13.8%	4.5%	8.9%	6.0%	7.4%
Rev Chg 3Y Avg	14.6%	-3.9%	6.5%	2.6%	3.7%	1.8%	3.2%
Rev Chg Q	-8.4%	4.2%	14.4%	9.1%	7.5%	9.6%	8.3%
QoQ Delta Rev Chg LTM	-1.8%	1.1%	3.7%	2.1%	1.8%	2.1%	2.0%
Op Mgn LTM	8.4%	6.6%	4.8%	17.7%	22.5%	31.9%	13.0%
Op Mgn 3Y Avg	-14.8%	7.4%	7.2%	16.4%	24.2%	30.8%	11.9%
QoQ Delta Op Mgn LTM	2.3%	-0.2%	-1.4%	0.6%	0.4%	0.1%	0.2%
CFO/Rev LTM	7.2%	6.7%	8.5%	20.6%	23.8%	26.6%	14.6%
CFO/Rev 3Y Avg	-8.9%	6.8%	12.7%	21.4%	26.1%	28.4%	17.1%
FCF/Rev LTM	2.6%	5.1%	1.8%	18.1%	22.1%	23.5%	11.6%
FCF/Rev 3Y Avg	-17.6%	5.5%	4.6%	18.6%	24.6%	25.6%	12.1%

Valuation

	ICCC	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	ImmuCell	HP	Hewlett .	Internat.	Cisco Sy.	Apple
Mkt Cap	0.1	21.9	32.6	284.9	309.2	4,074.4	158.8
P/S	2.0	0.4	1.0	4.4	5.4	10.0	3.2
P/EBIT	19.7	6.8	19.9	25.1	22.5	31.3	21.2
P/E	23.8	8.6	572.7	36.0	29.9	41.0	33.0
P/CFO	27.8	5.9	11.2	21.1	22.5	37.5	21.8
Total Yield	4.2%	14.1%	2.3%	5.0%	5.4%	2.8%	4.6%
Dividend Yield	0.0%	2.5%	2.1%	2.2%	2.1%	0.4%	2.1%
FCF Yield 3Y Avg	-7.3%	10.6%	5.5%	6.4%	6.0%	3.1%	5.7%
D/E	0.2	0.5	0.7	0.2	0.1	0.0	0.2
Net D/E	0.2	0.3	0.6	0.2	0.0	0.0	0.2

Returns

	ICCC	HPQ	HPE	IBM	CSCO	AAPL	Median
Name	ImmuCell	HP	Hewlett .	Internat.	Cisco Sy.	Apple
1M Rtn	27.5%	-1.8%	14.4%	0.6%	2.7%	-1.5%	1.7%
3M Rtn	1.5%	-11.9%	2.7%	7.9%	17.0%	7.1%	4.9%
6M Rtn	-9.3%	-4.0%	34.5%	6.6%	15.2%	36.3%	10.9%
12M Rtn	28.8%	-27.3%	14.2%	39.2%	33.7%	6.0%	21.5%
3Y Rtn	-3.8%	-3.8%	67.7%	139.0%	79.5%	113.4%	73.6%
1M Excs Rtn	28.3%	-5.6%	12.9%	-2.2%	-0.0%	-3.7%	-1.1%
3M Excs Rtn	-2.8%	-16.2%	-1.7%	3.6%	12.7%	2.8%	0.6%
6M Excs Rtn	-21.6%	-16.3%	22.3%	-5.7%	3.0%	24.0%	-1.3%
12M Excs Rtn	13.9%	-42.9%	-0.7%	25.0%	19.9%	-8.4%	6.6%
3Y Excs Rtn	-84.5%	-83.5%	-11.2%	59.6%	-1.2%	28.4%	-6.2%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for Morenull

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	9/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	11/13/2025	3/28/2025	4/1/2024	3/29/2023	3/30/2022	3/30/2021	3/27/2020
Key Financials
Total Revenue	28	26	17	19	19	15	14
EBITDA	6	1	-3	0	3	2	1
Operating Income	2	-2	-6	-2	0	-1	-1
Net Income	2	-2	-6	-2	-0	-1	-1
EPS	0.26	-0.26	-0.75	-0.32	-0.01	-0.14	-0.19
Growth Rates
Total Revenue Growth	16.5%	51.6%	-5.9%	-3.5%	25.4%	11.8%	24.9%
EBITDA Growth	1077.1%	141.0%	-842.9%	-87.0%	56.2%	20.7%	1518.9%
Operating Income Growth	171.3%	71.5%	-150.0%	-993.2%	118.6%	-44.7%	55.6%
Net Income Growth	161.0%	62.7%	-131.6%	-3085.3%	92.3%	21.1%	44.2%
Margins
EBITDA Margin	19.8%	4.0%	-14.9%	1.9%	14.0%	11.3%	10.4%
Operating Income Margin	8.4%	-6.2%	-32.9%	-12.4%	1.3%	-9.0%	-7.0%
Net Income Margin	8.4%	-8.1%	-33.1%	-13.4%	-0.4%	-6.7%	-9.4%
Cash & Debt
Total Cash	4	4	1	6	10	8	9
Total Debt	14	15	17	12	10	11	8
Net Debt / (Cash)	10	11	16	7	0	3	-0
Cash Flows
Net Cash from Operations	2	0	-5	-2	1	1	0
Free Cash from Operations	1	-0	-7	-6	-2	-3	-1
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4
Period End	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022
Filing Date	11/13/2025	8/14/2025	5/14/2025	3/28/2025	11/13/2024	8/13/2024	5/14/2024	4/1/2024	11/13/2023	8/10/2023	5/11/2023	3/29/2023
Key Financials Quarterly
Total Revenue	6	6	8	8	6	5	7	5	5	4	3	4
Ebitda	1	1	2	1	0	-1	0	-0	-0	-1	-2	-1
Operating Income	0	1	1	1	-1	-1	-0	-1	-1	-1	-2	-2
Net Income	-0	1	1	1	-1	-2	-0	-1	-1	-1	-2	-2
EPS	-0.02	0.06	0.16	0.06	-0.09	-0.20	-0.06	-0.15	-0.12	-0.18	-0.30	-0.21
Key Financials TTM
Total Revenue TTM	28	28	27	26	24	23	21	17	16	16	16	19
Ebitda TTM	6	5	3	1	-1	-1	-1	-3	-3	-3	-2	0
Operating Income TTM	2	2	-0	-2	-3	-4	-4	-6	-6	-6	-5	-2
Net Income TTM	2	2	-0	-2	-4	-4	-4	-6	-6	-6	-5	-2
Growth Rates Quarterly
Total Revenue Growth	-8.4%	17.8%	11.2%	52.1%	11.4%	54.9%	110.6%	30.3%	12.5%	-8.5%	-42.6%	-28.2%
EBITDA Growth	500.1%	280.9%	511.8%	510.8%	204.5%	-18.5%	123.4%	66.6%	-250.7%	-1842.5%	-229.3%	-229.2%
Operating Income Growth	103.5%	141.1%	472.5%	161.9%	51.4%	-6.3%	86.7%	38.6%	-92.0%	-110.7%	-495.4%	-1223.5%
Net Income Growth	80.1%	132.8%	430.5%	145.1%	25.4%	-11.0%	81.1%	31.7%	-43.5%	-101.7%	-551.0%	-2349.8%
Margins Quarterly
EBITDA Margin	11.8%	20.1%	27.8%	17.0%	1.8%	-13.1%	5.0%	-6.3%	-1.9%	-17.1%	-45.5%	-24.6%
Operating Income Margin	0.4%	8.8%	13.9%	8.0%	-9.6%	-25.3%	-4.1%	-19.7%	-21.9%	-36.9%	-65.5%	-41.8%
Net Income Margin	-2.5%	7.8%	17.9%	6.6%	-11.7%	-28.0%	-6.0%	-22.4%	-17.4%	-39.1%	-67.2%	-42.6%
Cash & Debt
Total Cash	4	6	5	4	4	1	1	1	2	1	3	6
Total Debt	14	14	15	15	16	16	16	17	17	15	13	12
Net Debt / (Cash)	10	8	10	11	12	15	15	16	15	14	10	7
Cash Flows Quarterly
FCF from Operations	-1	2	2	-0	-1	1	0	-1	-1	-1	-3	-1
Cash Flows TTM
FCF from Operations TTM	2	3	2	0	-0	-0	-1	-5	-5	-6	-5	-2
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	0.2%	4.5%	8.6%	4.6%	-4.4%	-10.7%	-2.3%	-7.6%	-9.2%	-10.4%	-19.3%	-15.1%
Return on Invested Capital (ROIC) TTM
ROIC TTM	4.5%	3.4%	-0.4%	-3.1%	-6.2%	-7.5%	-7.3%	-10.9%	-12.4%	-11.6%	-11.0%	-5.3%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Scours	17	18	19	15	13
Mastitis	0	0
Other	0	0	0		0
Unallocated				0
Other animal health					0
Total	17	19	19	15	14

Operating Income by Segment

$ Mil	2024	2023	2022	2021
Scours	1	6	7	5
Other	-2	-2	-2
Mastitis	-5	-6
Re-Tain®			-4	-4
Unallocated				-2
Total	-6	-2	0	-1

Assets by Segment

$ Mil	2024	2023	2022
Scours	25	21	22
Mastitis	18	18
Other	1	6
Re-Tain®			22
Total	44	45	44

Price Behavior

Price Behavior

Market Price	$6.12
Market Cap ($ Bil)	0.1
First Trading Date	07/10/1995
Distance from 52W High	-19.5%
	50 Days	200 Days
DMA Price	$5.73	$5.92
DMA Trend	indeterminate	down
Distance from DMA	6.8%	3.3%
	3M	1YR
Volatility	57.1%	61.6%
Downside Capture	199.38	84.22
Upside Capture	166.94	97.10
Correlation (SPY)	19.0%	12.3%

ICCC Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	2.00	0.85	1.11	1.07	0.41	0.29
Up Beta	0.04	-0.07	-0.38	0.76	0.15	0.24
Down Beta	-6.00	-0.83	-0.80	0.31	0.13	0.30
Up Capture	170%	62%	124%	77%	85%	5%
Bmk +ve Days	13	26	39	74	142	427
Stock +ve Days	9	21	29	58	121	354
Down Capture	429%	243%	286%	198%	90%	67%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	11	21	33	65	120	363

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

		Comparison of ICCC With Other Asset Classes (Last 1Y)
	ICCC	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	38.8%	15.1%	17.8%	72.1%	8.6%	4.4%	-8.3%
Annualized Volatility	61.7%	17.2%	19.4%	19.3%	15.2%	17.0%	35.0%
Sharpe Ratio	0.77	0.65	0.72	2.70	0.34	0.09	-0.08
Correlation With Other Assets		10.9%	12.2%	7.7%	11.0%	5.6%	3.1%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of ICCC With Other Asset Classes (Last 5Y)
	ICCC	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-0.8%	8.4%	14.7%	18.7%	11.5%	4.6%	30.8%
Annualized Volatility	55.4%	14.5%	17.1%	15.5%	18.7%	18.9%	48.7%
Sharpe Ratio	0.20	0.40	0.70	0.97	0.50	0.16	0.57
Correlation With Other Assets		5.2%	7.5%	7.3%	5.2%	3.1%	6.4%

Based On 10-Year Data

		Comparison of ICCC With Other Asset Classes (Last 10Y)
	ICCC	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-2.1%	9.9%	14.8%	15.3%	7.0%	5.3%	69.2%
Annualized Volatility	52.7%	16.6%	18.0%	14.7%	17.6%	20.8%	55.8%
Sharpe Ratio	0.17	0.49	0.71	0.86	0.32	0.22	0.90
Correlation With Other Assets		5.0%	6.4%	1.7%	4.0%	3.9%	3.3%

Short Interest

Short Interest: As Of Date	12152025
Short Interest: Shares Quantity	15,418
Short Interest: % Change Since 11302025	147.1%
Average Daily Volume	18,731
Days-to-Cover Short Interest	1
Basic Shares Quantity	9,045,851
Short % of Basic Shares	0.2%

Returns Analyses

	Title
0	Would You Still Hold ImmuCell Stock If It Fell 30%?

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
10/7/2025	2.2%	1.1%	-2.3%
7/9/2025	1.8%	-5.6%	-6.8%
4/8/2025	2.6%	12.1%	6.9%
1/10/2025	0.4%	1.2%	5.0%
10/8/2024	-0.3%	-3.0%	-3.6%
7/9/2024	-2.3%	-0.5%	-12.6%
4/9/2024	-0.4%	-3.3%	0.6%
1/8/2024	5.0%	10.0%	7.1%
...
SUMMARY STATS
# Positive	17	14	13
# Negative	8	11	12
Median Positive	3.2%	4.7%	6.3%
Median Negative	-0.5%	-3.3%	-3.6%
Max Positive	10.3%	14.9%	84.3%
Max Negative	-4.9%	-7.7%	-12.6%

	Forward Returns
10/7/2025	2.2%	1.1%	-2.3%
7/9/2025	1.8%	-5.6%	-6.8%
4/8/2025	2.6%	12.1%	6.9%
1/10/2025	0.4%	1.2%	5.0%
10/8/2024	-0.3%	-3.0%	-3.6%
7/9/2024	-2.3%	-0.5%	-12.6%
4/9/2024	-0.4%	-3.3%	0.6%
1/8/2024	5.0%	10.0%	7.1%
10/5/2023	4.0%	-3.3%	-1.3%
7/11/2023	4.0%	9.2%	0.8%
4/5/2023	0.4%	-2.0%	-1.0%
1/9/2023	8.5%	14.7%	10.8%
10/5/2022	2.5%	2.8%	6.3%
7/7/2022	1.2%	4.0%	6.7%
4/11/2022	-4.9%	-6.6%	-12.1%
1/5/2022	10.3%	2.4%	-2.5%
10/6/2021	3.2%	-4.2%	-7.3%
7/7/2021	-0.7%	-5.9%	-3.7%
4/7/2021	-0.2%	-7.7%	4.1%
1/7/2021	4.8%	4.7%	84.3%
10/6/2020	1.6%	4.7%	-4.0%
7/7/2020	3.6%	14.9%	5.8%
4/2/2020	3.5%	6.1%	13.4%
1/22/2020	-1.2%	-1.3%	-0.6%
11/12/2019	-0.2%	0.3%	2.3%
SUMMARY STATS
# Positive	17	14	13
# Negative	8	11	12
Median Positive	3.2%	4.7%	6.3%
Median Negative	-0.5%	-3.3%	-3.6%
Max Positive	10.3%	14.9%	84.3%
Max Negative	-4.9%	-7.7%	-12.6%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
9302025	11132025	10-Q 9/30/2025
6302025	8142025	10-Q 6/30/2025
3312025	5142025	10-Q 3/31/2025
12312024	3282025	10-K 12/31/2024
9302024	11132024	10-Q 9/30/2024
6302024	8132024	10-Q 6/30/2024
3312024	5142024	10-Q 3/31/2024
12312023	4012024	10-K 12/31/2023
9302023	11132023	10-Q 9/30/2023
6302023	8102023	10-Q 6/30/2023
3312023	5112023	10-Q 3/31/2023
12312022	3292023	10-K 12/31/2022
9302022	11212022	10-Q 9/30/2022
6302022	8112022	10-Q 6/30/2022
3312022	5122022	10-Q 3/31/2022
12312021	3302022	10-K 12/31/2021

Insider Activity

Expand for Morenull

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

ImmuCell (ICCC)

Market Price (12/27/2025): $6.13 | Market Cap: $55.5 MilSector: Health Care | Industry: Biotechnology

ImmuCell (ICCC)

Market Price (12/27/2025): $6.13Market Cap: $55.5 MilSector: Health CareIndustry: Biotechnology

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

ICCC Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About ImmuCell (ICCC)

First Defense® Product Line (Calf Scours Prevention)

Re-Tain® (Bovine Mastitis Treatment)

Interactive Breakdown

Better Bets than ImmuCell (ICCC)

INDUSTRY: Biotechnology

Higher Rev Chg 3Y Avg | Lower P/S (Values for ICCC: 14.6% | 2.0x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ICCC: 14.6% | 23.8x)

Higher Rev Chg LTM (Value for ICCC: 16.5%)

Higher Rev Chg 3Y Avg (Value for ICCC: 14.6%)

Higher Op Mgn LTM (Value for ICCC: 8.4%)

Higher CFO/Rev LTM (Value for ICCC: 7.2%)

Higher FCF/Rev LTM (Value for ICCC: 2.6%)

Higher Total Yield (Value for ICCC: 4.2%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for ICCC: 14.6% | 2.0x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ICCC: 14.6% | 23.8x)

Higher Rev Chg LTM (Value for ICCC: 16.5%)

Higher Rev Chg 3Y Avg (Value for ICCC: 14.6%)

Higher Op Mgn LTM (Value for ICCC: 8.4%)

Higher CFO/Rev LTM (Value for ICCC: 7.2%)

Higher FCF/Rev LTM (Value for ICCC: 2.6%)

Higher Total Yield (Value for ICCC: 4.2%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for ICCC: 14.6% | 2.0x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ICCC: 14.6% | 23.8x)

Higher Rev Chg LTM (Value for ICCC: 16.5%)

Higher Rev Chg 3Y Avg (Value for ICCC: 14.6%)

Higher Op Mgn LTM (Value for ICCC: 8.4%)

Higher CFO/Rev LTM (Value for ICCC: 7.2%)

Higher FCF/Rev LTM (Value for ICCC: 2.6%)

Higher Total Yield (Value for ICCC: 4.2%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for ImmuCell

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Market Price (12/27/2025): $6.13 | Market Cap: $55.5 Mil
Sector: Health Care | Industry: Biotechnology

Market Price (12/27/2025): $6.13
Market Cap: $55.5 Mil
Sector: Health Care
Industry: Biotechnology